Advaxis Inc Cmn Stk (ADXS) 11.52 $ADXS Advaxis
Post# of 273257
Posted On: 09/03/2016 7:11:08 AM
Advaxis Inc Cmn Stk (ADXS) 11.52 $ADXS
Advaxis Secures a $30M Direct Placement Financing to Healthcare Specialist Investors
GlobeNewswire - Tue Aug 16, 8:31AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare institutional specialist investors to sell approximately 2.2 million shares of its common stock at a price of $13.50 per share in a registered direct offering for gross proceeds of approximately $30 million. The offering is expected to close on or about August 19, 2016, subject to customary closing conditions.
ADXS: 11.52 (-0.26)
Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
GlobeNewswire - Thu Aug 11, 7:00AM CDT
AXAL meets stage 1 primary objective, demonstrates increased systemic HPV-reactive T-cell responses
ADXS: 11.52 (-0.26)
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
PR Newswire - Tue Aug 02, 7:00AM CDT
Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. This collaboration brings together Amgen's development expertise in immuno-oncology with Advaxis' MINE(TM) (My Immunotherapy Neo-Epitopes) program, which is uniquely positioned to develop a customized approach to cancer treatment.
ADXS: 11.52 (-0.26), AMGN: 169.77 (-0.36)
Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 11.52 (-0.26)
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 11.52 (-0.26)
Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 11.52 (-0.26)
UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 11.52 (-0.26)
Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 11.52 (-0.26)
FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 11.52 (-0.26)
Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 11.52 (-0.26)
AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 11.52 (-0.26)
Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 11.52 (-0.26)
Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 11.52 (-0.26)
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 11.52 (-0.26), MRK: 62.98 (+0.08)
Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 11.52 (-0.26)
Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 11.52 (-0.26)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AVXL: 3.05 (+0.02), AMBX: (), ACH: 9.32 (+0.06), AMGN: 169.77 (-0.36), ADMP: 2.83 (+0.02), ABBV: 64.12 (+0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), AVXL: 3.05 (+0.02), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), ARRY: 3.50 (-0.02)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 11.52 (-0.26), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), ATNM: 1.70 (-0.06), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), ABBV: 64.12 (+0.09), BXLT: 46.02 (-0.18), ARRY: 3.50 (-0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.43 (-0.05), AMBX: (), CLDX: 3.35 (-0.01), ARQL: 1.40 (unch), CTIC: 0.39 (unch), CTMX: 12.07 (+0.35), ABBV: 64.12 (+0.09), XLRN: 30.84 (+0.59), ADXS: 11.52 (-0.26), AMGN: 169.77 (-0.36), BIND: 0.78 (-0.09), BMY: 56.35 (-0.41), BPTH: 1.55 (-0.03), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), CELGZ: 1.18 (+0.05)
Advaxis Secures a $30M Direct Placement Financing to Healthcare Specialist Investors
GlobeNewswire - Tue Aug 16, 8:31AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare institutional specialist investors to sell approximately 2.2 million shares of its common stock at a price of $13.50 per share in a registered direct offering for gross proceeds of approximately $30 million. The offering is expected to close on or about August 19, 2016, subject to customary closing conditions.
ADXS: 11.52 (-0.26)
Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
GlobeNewswire - Thu Aug 11, 7:00AM CDT
AXAL meets stage 1 primary objective, demonstrates increased systemic HPV-reactive T-cell responses
ADXS: 11.52 (-0.26)
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
PR Newswire - Tue Aug 02, 7:00AM CDT
Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. This collaboration brings together Amgen's development expertise in immuno-oncology with Advaxis' MINE(TM) (My Immunotherapy Neo-Epitopes) program, which is uniquely positioned to develop a customized approach to cancer treatment.
ADXS: 11.52 (-0.26), AMGN: 169.77 (-0.36)
Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 11.52 (-0.26)
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 11.52 (-0.26)
Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 11.52 (-0.26)
UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 11.52 (-0.26)
Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 11.52 (-0.26)
FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 11.52 (-0.26)
Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 11.52 (-0.26)
AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 11.52 (-0.26)
Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 11.52 (-0.26)
Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 11.52 (-0.26)
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 11.52 (-0.26), MRK: 62.98 (+0.08)
Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 11.52 (-0.26)
Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 11.52 (-0.26)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), AVXL: 3.05 (+0.02), AMBX: (), ACH: 9.32 (+0.06), AMGN: 169.77 (-0.36), ADMP: 2.83 (+0.02), ABBV: 64.12 (+0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 11.52 (-0.26), ADRO: 14.49 (+0.27), ARWR: 7.15 (+0.09), ADMP: 2.83 (+0.02), AMGN: 169.77 (-0.36), APTO: 2.20 (+0.16), AVXL: 3.05 (+0.02), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), ARRY: 3.50 (-0.02)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 11.52 (-0.26), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), ATNM: 1.70 (-0.06), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), ABBV: 64.12 (+0.09), BXLT: 46.02 (-0.18), ARRY: 3.50 (-0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.43 (-0.05), AMBX: (), CLDX: 3.35 (-0.01), ARQL: 1.40 (unch), CTIC: 0.39 (unch), CTMX: 12.07 (+0.35), ABBV: 64.12 (+0.09), XLRN: 30.84 (+0.59), ADXS: 11.52 (-0.26), AMGN: 169.77 (-0.36), BIND: 0.78 (-0.09), BMY: 56.35 (-0.41), BPTH: 1.55 (-0.03), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), CELGZ: 1.18 (+0.05)
(0)
(0)Scroll down for more posts ▼